Skip to main content

Pathogen Genomic Surveillance

WHO and partners announce grants to boost pathogen genomic surveillance


The World Health Organization (WHO) and partners announced 10 projects that will receive almost US$ 2 million in grants to improve capacities in pathogen genomic surveillance.

The catalytic grant fund was established by the International Pathogen Surveillance Network (IPSN) to support partners from low- and middle-income countries to build their capacities in pathogen genomic analysis. This technology analyses the genetic code of viruses, bacteria and other disease-causing organisms to understand, in conjunction with other data, how easily they spread, and how sick they can make people. This data allows scientists and public health teams to track and respond to infectious disease threats, supports the development of vaccines and treatments and empowers countries to take faster decisions.

The fund is hosted by the United Nations Foundation and supported by the Bill & Melinda Gates Foundation, The Rockefeller Foundation and Wellcome.

"The IPSN catalytic grant fund recipients will accelerate the benefits of pathogen genomic surveillance in low- and middle-income settings, as well as explore new applications for genomic surveillance, such as wastewater surveillance," said Manisha Bhinge, Vice President of the Health Initiative at The Rockefeller Foundation. "Pandemics and epidemics continue to be a global threat, further amplified by climate change. There is urgent need for equitable access to these tools and capabilities to protect lives in vulnerable communities."

One of the recipients, the American University of Beirut, will use wastewater surveillance to study how diseases spread in refugee populations, helping to ensure that people can quickly receive the care and support they need in migration settings. Another grantee, the Pasteur Institute of Laos, will use the funding to develop new methods to track avian flu in live-bird markets, a setting that is often overlooked but vital to millions of people worldwide.

"If we are to protect vulnerable populations from the devastating impacts of disease, we first need to better understand how these pathogens spread, evolve and cause illness. These projects, developed in-country and tailored to local priorities, will generate new insights, knowledge and evidence that will help track global pathogen trends and inform evidence-based decisions to implement effective interventions" said Titus Divala, Interim Head of Epidemics and Epidemiology at Wellcome.

The Federal University of Rio de Janeiro in Brazil will use the funding to develop an open-source bioinformatics tool that can be used to conduct offline analyses. The tool will be piloted in Latin America with potential for global use, especially in low-resource settings.

"SARS-CoV-2 and subsequent regional disease outbreaks have underscored the importance of access to genomic surveillance tools in all countries. The IPSN's catalytic investments will generate data and innovative methods to support the much-needed scale-up in LMICs," said Simon Harris of the Gates Foundation.

The grantees were announced at the IPSN Global Partners Forum held in Bangkok, Thailand, from 21–22 November. The event was co-hosted by the WHO Regional Offices for South-East Asia and the Western Pacific and the Centre for Pathogen Genomics at the Doherty Institute in Australia.

Pathogen genomic surveillance, infectious disease monitoring, genomic epidemiology, whole-genome sequencing, outbreak investigation, pathogen evolution, genetic diversity, molecular epidemiology, antimicrobial resistance, viral genomics, bacterial genomics, metagenomics, phylogenetic analysis, public health genomics, data sharing, genomic databases, bioinformatics tools, surveillance networks, epidemic preparedness, genomic sequencing platforms, pathogen tracking, genomic mutations, genomic data analysis, early outbreak detection, global health security, pandemic response

#PathogenGenomics, #GenomicSurveillance, #InfectiousDisease, #OutbreakResponse, #MolecularEpidemiology, #PublicHealth, #AntimicrobialResistance, #Phylogenetics, #DataSharing, #GlobalHealth, #DiseaseMonitoring, #ViralGenomics, #BacterialGenomics, #Metagenomics, #PandemicPreparedness, #HealthSecurity, #Bioinformatics, #GenomicEpidemiology, #PathogenEvolution, #SurveillanceScience, #EpidemicControl, #WholeGenomeSequencing, #EarlyDetection, #GenomicData, #HealthInnovation

International Conference on Genetics and Genomics of Diseases 




For Enquiries: genetics@healthcarek.com 

Get Connected Here 
--------------------------------- 
--------------------------------- 

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...
Post a Comment
Read more